Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

A legfontosabb adatok

Ki végzi
University of Maryland, Baltimore
Hol
Baltimore (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
1 fő vett részt
Kezdés
2023. máj. 8.
Befejezés
2025. dec. 25.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Pioglitazone 15mg
A regiszteradat frissítve
2026. április 28.
Miért állt le
Loss of Financial Sponsor

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18-80 years
  • CT scan demonstrating an acute, spontaneous, primary basal ganglia ICH
  • ICH volume between 30 - 80 mL as calculated by the ABC/2 method
  • Study intervention can reasonably be initiated within 24 hours after the onset of stroke symptoms. In situations with unclear time of onset, then the onset will be considered the time that the subject was last known to be well
  • Glasgow Coma Score (GCS) 5 - 14
  • Historical Modified Rankin Score 0 or 1
  • Consent by patient or LAR to MIS evacuation of the ICH based on best medical practice1
  • Time to pioglitazone treatment ≤ 24 hours from symptom onset or TLKN1

Ki nem vehet részt

  • Participation in a concurrent interventional medical investigation or clinical trial
  • Known life-expectancy of less than 6 months, no reasonable expectation of recovery, Do-Not-Resuscitate (DNR), or comfort measures only prior to randomization
  • T2DM treated with insulin or an oral medication including Glyburide, unless the NICU physician deems it safe to replace the T2DM medication with pioglitazone1
  • Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, hemorrhagic conversion of an ischemic infarct, or bleeding into a known neoplastic lesion
  • NIHSS< 5, bilateral fixed dilated pupils, extensor motor posturing, unstable mass or evolving intracranial compartment syndrome
  • Intraventricular extension of the hemorrhage estimated to involve >50% of either of the lateral ventricles (External ventricular drain (EVD) to treat intracranial pressure (ICP) or hydrocephalus is allowed)
  • Primary thalamic ICH or infratentorial intraparenchymal hemorrhage including midbrain, pons or cerebellum
  • Evidence of active bleeding involving a retroperitoneal, gastrointestinal, genitourinary, or respiratory tract site
  • Use of anticoagulants that cannot be rapidly reversed, uncorrected coagulopathy or known clotting disorder
  • Patients with a mechanical heart valve (presence of bioprosthetic valve(s) is permitted)
  • Homelessness or history of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • intolerance or allergy to any TZD1
  • heart failure (symptomatic or NYHA Class I-IV or newly diagnosed on admission TTE screening)
  • Severe kidney or liver disease (serum ALT > 2.5 x ULN) with active coagulopathy
  • Platelet count < 75,000
  • International Normalized Ratio (INR) > 1.4 after correction or inability to sustain INR ≤ 1.4 using short- and long-active procoagulants (such as, but not limited to, NovoSeven, fresh frozen plasma, vitamin K, Kcentra or Feiba)
  • Untreatable elevated activated partial thromboplastin time (aPTT)
  • Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or is post-menopausal
  • patients with abnormal (>1x upper limit of normal) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin
  • Patients requiring long-term anticoagulation that needs to be initiated < 5 days from index ICH; patient must not require Coumadin (anticoagulation) during the first 30 days (reversal of anticoagulation is permitted for medically stable patients who can safely tolerate the short-term risk of reversal)
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent

Helyszínek itt: Egyesült Államok

  • University of Maryland, BaltimoreBaltimore, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.

A vizsgálat 2 csoportja

  • MIPS + PioglitazoneA vizsgált kezelés

    20 Subjects will undergo MIPS for evacuation of ICH using the BrainPath access device plus perioperative pioglitazone for 3 weeks

    Kezelés: Pioglitazone 15mg

  • MIPS AloneNincs vizsgálati kezelés, összehasonlításként

    This trial will compare it's subjects to subjects who have previously undergone MIPS for evacuation of ICH using the BrainPath access device as part of the ENRICH trial (NCT02880878). These subjects will be enrolled at an ENRICH trial site independent of our Institution. Deidentified patient information from 20 subjects in this group, who will be matched to those in the ENRICH-PLUS group, will be provided to the principal investigator for comparison of outcomes.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Non-Randomized Controlled Trial to Examine the Safety and Suitability of Supplementing Early Minimally Invasive Parafascicular Surgery (MIPS) for Clot Evacuation of Basal Ganglia Intracerebral Hemorrhage (ICH) With Pioglitazone
A regiszteradat frissítve
2026. április 28.